ADBIOTECH Jumps Without News; NEUROPHET Up 45% on Debut[K-Bio Pulse]

작성일 07-29

<div class="article_view" data-translation-body="true" data-tiara-layer="article_body" data-tiara-action-name="본문이미지확대_클릭"> 
         <section dmcf-sid="1lL5YZ8tDO">
          <div contents-hash="8c14a1616687e0bc98c62c7d0115f20d82583c62e0c239f4d0bd90bb92959bf4" dmcf-pid="tSo1G56FEs" dmcf-ptype="general">
           <div>
            This article was released as <strong>Pharm Edaily Premium Content</strong> on July 27, 2025, at 10:50 AM.
           </div>
          </div>
          <p contents-hash="771c49c4c0dbc2f17b61d0e1eb6e8b61135c4d01e793ecc1f81155abd9223468" dmcf-pid="FvgtH1P3rm" dmcf-ptype="general">[Kim Saemi, Edaily Reporter] On July 25, biotech and healthcare stock ADBIOTECH Co.,Ltd. (hereinafter ADBIOTECH) recorded the highest share price increase excluding newly listed NEUROPHET Inc. (hereinafter NEUROPHET)-rising 23.64%. NEUROPHET, an AI-powered medical imaging software company, made a smooth KOSDAQ debut with its stock price jumping 45% from its IPO price of 14,000 KRW on the first day.</p>
          <figure class="figure_frm origin_fig" contents-hash="f7938731aede4977144406961cfbd389c39dae7598939b84038e25e7deedd134" dmcf-pid="3TaFXtQ0sr" dmcf-ptype="figure">
           <p class="link_figure"><img alt="On July 25, NEUROPHET, newly listed on the KOSDAQ, topped the day’s list of biggest gainers. Among previously listed biotech stocks, ADBIOTECH recorded the highest gain, with its share price surging 23.64% that day. (Source: KG Zeroin MP Doctor)" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202507/29/Edaily/20250729125209640geya.jpg" data-org-width="515" dmcf-mid="Zq7cgAHEOC" dmcf-mtype="image" height="auto" src="https://img3.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202507/29/Edaily/20250729125209640geya.jpg" width="658"></p>
           <figcaption class="txt_caption default_figure">
            On July 25, NEUROPHET, newly listed on the KOSDAQ, topped the day’s list of biggest gainers. Among previously listed biotech stocks, ADBIOTECH recorded the highest gain, with its share price surging 23.64% that day. (Source: KG Zeroin MP Doctor)
           </figcaption>
          </figure>
          <div contents-hash="d6009a66b535b0e87d5ea3968e47d5ba5e9cbb7fda0c93afbdb4bc3eb81bf92f" dmcf-pid="0yN3ZFxpmw" dmcf-ptype="general">
           <strong>ADBIOTECH Rallies 57%-Company Says ‘No Material Change’</strong>
          </div>
          <p contents-hash="8e8a39f28f7f4e2a0193e06cf4b5688b629f5f63baacc19b5e7d9bbb7856ecb8" dmcf-pid="pWj053MUmD" dmcf-ptype="general">According to MP Doctor (formerly MarketPoint) by KG Zeroin, ADBIOTECH Co.,Ltd. (hereinafter ADBIOTECH) closed at 3,635 KRW on July 25, up 695 KRW (23.64%) from the previous day. </p>
          <p contents-hash="b65661d0eee0625d6316e7c7fe2b5214c198e66bb2b4a6ec8c3c32074ead5826" dmcf-pid="UYAp10RuwE" dmcf-ptype="general">Following gains of 320 KRW (13.82%) on July 23 and 305 KRW (11.57%) on July 24, ADBIOTECH extended its rally for a third consecutive trading day, with its stock surging 57% over the three-day period. Trading volume also spiked starting on July 23. While only 433,183 shares were traded up to July 22, volume jumped to 1,602,912 shares on July 23, 1,513,000 on July 24, and soared to 5,279,505 shares on July 25.</p>
          <figure class="figure_frm origin_fig" contents-hash="2fbc53747487dca368fccfb994156f1d15b51dfcd3d970148b7095b9ad4bda65" dmcf-pid="uPFodLvamk" dmcf-ptype="figure">
           <p class="link_figure"><img alt="Recent trends in ADBIOTECH‘s stock price and trading volume (Source: KG Zeroin MP Doctor)" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202507/29/Edaily/20250729125210994wtna.jpg" data-org-width="478" dmcf-mid="5gkuFUdzII" dmcf-mtype="image" height="auto" src="https://img2.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202507/29/Edaily/20250729125210994wtna.jpg" width="658"></p>
           <figcaption class="txt_caption default_figure">
            Recent trends in ADBIOTECH‘s stock price and trading volume (Source: KG Zeroin MP Doctor)
           </figcaption>
          </figure>
          <div contents-hash="9a8257be2008cc88d73c714cd6140c9dc08fea4f683196c16168fe223fc477dd" dmcf-pid="7Q3gJoTNrc" dmcf-ptype="general">
           ADBIOTECH is an eco-friendly biotechnology company that develops veterinary and human-use products based on various immuno-antibody research programs. Recently, the unlisted company OcupBioM decided to participate in ADBIOTECH’s third-party allotment capital increase, and is expected to become its largest shareholder. OcupBioM, co-led by Byunghak Yoon and Byunghwan Do, owns the intellectual property (IP) rights to the immuno-oncology drug “Oregovomab.”
          </div>
          <p contents-hash="dee1d21bb545583e3f50e86fdbd69c43c4bae6d960fbfd5b3a1628f672e05a67" dmcf-pid="zx0aigyjsA" dmcf-ptype="general">Oregovomab had reached Phase 3 clinical trials under the management of CanariaBio (now HYUNDAI FEED Inc.). However, the study was halted last year upon recommendation from the Data Safety Monitoring Board (DSMB), resulting in impairment losses exceeding 140 billion KRW. The aftermath led to the suspension of CanariaBio‘s trading, and on July 7, a delisting decision was rendered following a review by the Korea Exchange’s Corporate Review Committee.</p>
          <p contents-hash="c1c8e467fad89a52b3a1b513182304ca0e078a2c93b199dc37b815f0a0b1b7c5" dmcf-pid="qMpNnaWAIj" dmcf-ptype="general">In response to the recent sharp price volatility, ADBIOTECH stated, “There’s no particular favorable development,” and emphasized, “There are no material changes.” The Korea Exchange also stepped in. At 4:41 p.m. on July 25, the KOSDAQ Market Division of the Korea Exchange requested an inquiry disclosure regarding the unusual stock price fluctuation. The deadline for submission is 6:00 p.m. on July 28.</p>
          <p contents-hash="cf2136d0a3501201bf7e35d687d4b0afdd29b0debec65a6d6c98807c2f476ce1" dmcf-pid="BRUjLNYcsN" dmcf-ptype="general"><strong>NEUROPHET Jumps 45% on KOSDAQ Debut</strong></p>
          <p contents-hash="19562ca4cd6a483a93aa95e5e5e701d40a5d8635d82311fc479a2babac5a6ba7" dmcf-pid="beuAojGksa" dmcf-ptype="general">NEUROPHET’s shares rose as high as double the IPO price during intraday trading, eventually closing at 20,300 KRW?up 45% from its IPO price. The company specializes in software that analyzes brain MRI and PET scan data using AI technologies.</p>
          <p contents-hash="3242900fe5ea3198989583d5addff7c2729f7d952aad62cbfa1ff404c0d23965" dmcf-pid="Kd7cgAHEOg" dmcf-ptype="general">Its key products include:</p>
          <p contents-hash="a7900ca7532199d397c6090a927704632ef399e98f3eba1133b823dca796ac06" dmcf-pid="9JzkacXDIo" dmcf-ptype="general">Neurophet AQUA: for analyzing brain degeneration in MRI images,</p>
          <p contents-hash="5648f30c18a20f68c05b6dd12c13cab8040729002437d2c225c7bd88361715a3" dmcf-pid="2iqENkZwwL" dmcf-ptype="general">Neurophet SCALE PET: for quantifying PET scan data,</p>
          <p contents-hash="9ad35afdff696647967a54c5205fa8dd131a99acef7dce320d5b87f0f00d9251" dmcf-pid="VnBDjE5rDn" dmcf-ptype="general">Neurophet AQUA AD: for monitoring prescription, efficacy, and side effects of Alzheimer’s treatments.</p>
          <p contents-hash="add8edd917eb85c91bb4780c70cf1b694e55c2b9130961cc11592ccb4092586c" dmcf-pid="f6tLenSgIi" dmcf-ptype="general">During its institutional investor book-building process, NEUROPHET recorded a competition ratio of 1,087.6 to 1, and its IPO price was set at the upper end of the target range (11,400~14,000 KRW). The general subscription phase saw even fiercer competition at 1,922.75 to 1, attracting 6.73 trillion KRW in deposits.</p>
          <p contents-hash="63a0d7c2a1208c675e4d7813e7da6efb3bac0cc9c8f751b266bae2fd6a9c3f53" dmcf-pid="4PFodLvawJ" dmcf-ptype="general">A NEUROPHET official commented, “The 45% rise on the debut day reflects some of the market’s expectations,” adding, “While it’s too early to judge the company’s value based solely on short-term stock movement, we’ll do our best in R&amp;D and business operations to maintain growth.”</p>
          <p contents-hash="a0dd4ab8c25d0205eb5cda96ec80c831e9fed46ebcf6027df25389313edcdef5" dmcf-pid="8Q3gJoTNrd" dmcf-ptype="general">The company is preparing for global expansion. It has secured 17 regulatory approvals in Korea, 5 in the U.S., 1 in Europe, and 6 in Japan, and is pursuing additional clearances. NEUROPHET is aiming to reach profitability by 2027.</p>
          <p contents-hash="f90daa76e95ac21389d9068093f4957395f48c69ef17041a243d1ad132c37471" dmcf-pid="6x0aigyjme" dmcf-ptype="general"><strong>NEXTBIOMEDICAL Gains on U.S. Prospects for ‘Nexphere-F’</strong></p>
          <p contents-hash="85e73fdeb11f47a415c49e6ea946318013c216a1eb75005c7215481bb0fb0b28" dmcf-pid="PMpNnaWAIR" dmcf-ptype="general">NEXTBIOMEDICAL CO., LTD. (hereinafter NEXTBIOMEDICAL) closed at 57,300 KRW, up 4,300 KRW (8.11%). The rise is attributed to growing anticipation over its degradable pain embolization agent ‘Nexphere-F’ entering the U.S. market.</p>
          <p contents-hash="84f53b63e185400c2646ca331c679aa5dc3a69de0f95e6c7216f1695bd6eb5af" dmcf-pid="QRUjLNYcOM" dmcf-ptype="general">Nexphere-F is used in localized pain procedures that block abnormal blood vessels responsible for pain by temporarily embolizing the blood flow and nutrient supply. Unlike systemic or short-acting drug treatments, Nexphere-F provides targeted therapy by directly intervening in the pathological cause.</p>
          <p contents-hash="d06966902e9997389243466c5fc4015eeec2f70c3e8db861918436dd56e0d948" dmcf-pid="xeuAojGkOx" dmcf-ptype="general">NEXTBIOMEDICAL is expected to initiate FDA clinical trials for Nexphere-F in Q3 of this year?marking a key step toward commercialization in the U.S. The company aims to secure FDA approval by 2027 and has already launched the product in Europe.</p>
          <p contents-hash="e416c943d60d6404135e34e9472f6b6bff90a333c50bf2e45b068d50c4eb0c0a" dmcf-pid="yGcUtpe7wQ" dmcf-ptype="general">The stock has now risen for three consecutive sessions. A NEXTBIOMEDICAL representative stated, “There’s growing optimism as discussions over Nexphere-F’s overseas licensing become more visible,” adding, “Although the product is already available in Europe, the U.S. clinical program has not yet started, so this progress likely influenced investor sentiment.”</p>
          <p contents-hash="009d1f44390811b0f6197f5eb17408f960282512b5444c68516965fba3cc7b99" dmcf-pid="WHkuFUdzEP" dmcf-ptype="general">김새미 (bird@edaily.co.kr) </p>
         </section> 
        </div> 
        <p class="" data-translation="true">Copyright © 이데일리. 무단전재 및 재배포 금지.</p>

이전

임형준, 그물 손질에 바다 입수까지…진짜 잠수부 아냐?

07-29
다음

'금21 은9 동27' 한국, 2025 라인루르세계대학경기대회 종합 4위 달성

07-29

등록된 댓글이 없습니다.

로그인한 회원만 댓글 등록이 가능합니다.

먹튀폴리스

ADBIOTECH Jumps Without News; NEUROPHET Up 45% on Debut[K-Bio Pulse]

멤버랭킹

관련자료

멤버랭킹